SBIR-STTR Award

geneXwell: Multidimensional Omic Risk Models and Dynamic Visualizations to Drive Positive Change in Employee Behavioral Economics
Award last edited on: 3/16/2022

Sponsored Program
SBIR
Awarding Agency
NIH : NHGRI
Total Award Amount
$16,734
Award Phase
1
Solicitation Topic Code
172
Principal Investigator
Aashutosh Misra

Company Information

Genexwell Inc

3909 Caminito Del Mar Surf
San Diego, CA 92130
   (847) 636-6844
   N/A
   www.genexwell.com
Location: Single
Congr. District: 50
County: San Diego

Phase I

Contract Number: 1R43HG011825-01A1
Start Date: 9/21/2021    Completed: 3/31/2022
Phase I year
2021
Phase I Amount
$16,734
Employee productivity is directly related to employee health, providing employers strong financial incentivesto deploy preventative health programs. One of the most challenging & costly chronic conditions is coronary artery disease (CAD). Most employers spend a significant portion of overall benefits (40-45%) managing &treating symptoms and risk factors associated with CAD. Each CAD event (heart attack, angina) and related procedures (stents, CABG) costs the employer $125k in direct medial and productivity costs. These CAD events are also the number 1 cause of death in the United States. Self-insured employers, which provide health coverage to 100M individuals in the US, bear the costs of CAD directly. Therefore, any cost-effective approachable to reduce CAD incidence in employee populations, particularly through early interventions would have significant societal and economic benefits. geneXwell provides this opportunity by targeting the delivery of our world-class digital preventative cardiology program to those employees most at risk for CAD and most likely to benefit from lipid lowering therapy. As partof ordinary employee health risk assessment, employees provide screening samples for clinical and genomicanalysis. Standard demographic and biometric risk factors are combined with a genetic risk estimate, resulting in a personalized CAD risk score per employee. The addition of genetic risk both improves risk stratification ascompared to standard clinical guidelines and, more importantly, identifies the nature of risk and the most effective interventions. This strategy is validated and supported by the research of our co-founders at The ScrippsResearch Translational Institute. In the employee setting, this comprehensive risk modeling is used to stratifythe employee pool into risk tiers, and analytics run to determine the cost vs benefit of lifestyle vs therapeuticintervention strategies for each risk tier. This information is then summarized and displayed via intuitivevisualization tools that allow employees to evaluate the benefits of prevention behaviors and health interventions.Dynamic visualizations tools will allow collaboration, shared decision making and visibility across allstakeholders. Revenue will be generated through Software as a Service and risk share models to employers. Phase I will target the extension of our established baseline risk model to the data available in an employerhealth setting, we will develop a prototype employee visualization interface, and conduct a usability study. First,we will build on our existing, validated polygenic CAD scoring model. We will develop and deploy a CAD riskscore personalized with genetic, demographic, and clinical factors to produce individualized CAD risk scores foremployees. A risk reducer interface will be developed to integrate prevention strategies and anticipated healthbenefits to drive employee behavioral change. Next, a prototype employee mobile platform will be developedwith focus on data synchronization across multiple domains and sources, as well as dynamic, intuitivevisualization tools, developed and informed by behavioral science expertise, to guide complex behavioral healthdecision making by employees. Once the prototype platform has been integrated at the system level and passesverification and validation testing, it will be deployed in a usability study with employees to validate interpretability.

Public Health Relevance Statement:
The objective is to demonstrate the feasibility of geneXwell-CAD, a predictive health and behavioral change platform to maximize employee health through multidimensional omic risk modeling and dynamic visualizations. Current US healthcare cost structures provide self-insured employers strong financial incentives to ensure employees remain healthy and productive. One of the most challenging & costly chronic conditions is coronary artery disease (CAD). GeneXwell aims to leverage modern predictive analytics and personalized healthcare algorithms, while protecting the privacy of employees, to identify the subpopulation of employees most at risk for adverse CAD outcomes, and to improve employee health and reduce long-term costs.

Project Terms:
Algorithms ; Ursidae Family ; Bears ; Ursidae ; bear ; Behavior ; Behavioral Sciences ; Biometry ; Biometrics ; Biostatistics ; Cardiology ; Cause of Death ; Coronary Arteriosclerosis ; Coronary Artery Disease ; Coronary Artery Disorder ; Coronary Atherosclerosis ; atherosclerotic coronary disease ; coronary arterial disease ; Data Analyses ; Data Analysis ; data interpretation ; Decision Making ; Disease ; Disorder ; Economics ; Goals ; Health ; Incidence ; Institutes ; Life Style ; Lifestyle ; Lipids ; Modernization ; Myocardial Infarction ; Cardiac infarction ; Myocardial Infarct ; cardiac infarct ; coronary attack ; coronary infarct ; coronary infarction ; heart attack ; heart infarct ; heart infarction ; Privatization ; Productivity ; Research ; Research Support ; Risk ; Risk Factors ; Running ; Social Marketing ; Stents ; Surveys ; Survey Instrument ; Testing ; United States ; Vision ; Sight ; visual function ; Employee Health ; Measures ; Privacy ; Health Care Costs ; Health Costs ; Healthcare Costs ; Health Benefit ; Risk Assessment ; Guidelines ; base ; improved ; Procedures ; Medial ; Area ; Chronic ; Clinical ; Phase ; Ensure ; insight ; Intuition ; Individual ; Policies ; Relative Risks ; Early Intervention ; Collaborations ; Genetic ; Diagnostic ; Nature ; programs ; Complex ; Event ; Source ; System ; behavior change ; empowered ; experience ; Employee ; Structure ; Disease Outcome ; Preventative strategy ; Preventive strategy ; Prevention strategy ; disease risk ; disorder risk ; Prevention ; Reporting ; intervention therapy ; Therapeutic Intervention ; Modeling ; Sampling ; behavioral health ; response ; Intervention Strategies ; interventional strategy ; Intervention ; Genomics ; Malus domestica ; Apple ; Data ; Genetic Risk ; Risk Estimate ; Translational Research ; Translational Science ; translation research ; Process ; Modification ; symptom management ; manage symptom ; Behavioral ; cost ; care systems ; care services ; digital ; Visualization software ; visualization tool ; targeted delivery ; site targeted delivery ; cost effective ; Population ; Coupled ; risk sharing ; encryption ; user centered design ; usability ; prototype ; effective intervention ; cyber security ; cybersecurity ; internet security ; financial incentive ; financial reward ; monetary incentive ; verification and validation ; shared decision making ; clinical risk ; screening ; behavioral economics ; mobile computing ; mobile platform ; mobile technology ; Theory of Change ; Predictive Analytics ; personalized health care ; personalized healthcare ; precision health care ; precision healthcare ; software as a service ; symptom treatment ; symptomatic treatment ; treat symptom ; risk stratification ; stratify risk ; Fast Healthcare Interoperability Resources ; FHIR ; Visualization ;

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----